"We just finished a successful clinical Proof-of-Concept study and are preparing for license negotiations with a large Pharma company"

Using our three stage approach enables you to determine an accurate and transparent value for your early clinical stage compound:

 

Stage 1 - Review of Target Product Profile & Clinical Development Plan.

A review of your TPP & CDP identifies target indication, time and risks associated with your program. 

Stage 2 - Cost & Revenue modeling High-level cost estimates are identified to determine the costs related to the clinical studies outlined in your CDP. Revenue estimates are modeled using standard techniques.

Stage 3 - Valuation In this final stage a risk adjusted approach is used to ultimately estimate a fair value for your your early clinical stage compound. The flexible models we use also allow for taking into account payment of milestones or cost-sharing. 

In addition we can also assist you with compiling a comprehensive Product Development Plan outlining the manufacturing/CMC, preclinical, clinical and regulatory strategy and tactics.

© 2020 by LFSCNC. LFSCNC is the trade name of HDH Consulting BVBA.